Irene Cao

Irene Cao

Auto-generated profile, based on publicly available information

Irene Cao

Cardiac Surgery Unit, Azienda Ospedale Università di Padova, 35122 Padova, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Open access
VALERIA PERGOLAVALERIA PERGOLA
VALERIA PERGOLA
NPNicola Pradegan
Nicola Pradegan
ECElena Cozza
Elena Cozza
Dan Alexandru CozacDan Alexandru Cozac
Dan Alexandru Cozac
ICIrene Cao
Irene Cao
RMRaffaella Motta
Raffaella Motta
Cardiac allograft vasculopathy (CAV) assessment post-heart transplantation (HT) typically relies on invasive coronary angiography (ICA). However, cardiac computed tomography angiography (CCTA) is emerging as a promising alternative due to its potential benefits in economic, safety, and logistical aspects. This study aimed to evaluate the impact of a CCTA program on these aspects in CAV surveillance post-HT. A retrospective single-center study was conducted between March 2021 and February 2023, involving HT patients who underwent either CCTA or ICA. Among 260 patients undergoing CAV surveillance, 115 (44.2%) patients underwent CCTA, and 145 (55.8%) patients underwent ICA. The CCTA group showed incurred lower overall costs (p ​< ​0.0001) and shorter hospitalization times (p ​< ​0.0001) compared to the ICA group. In terms of safety, CCTA surveillance required significantly lower contrast volumes (p ​< ​0.0001) and lower effective doses (p ​= ​0.03). CCTA emerges as a safe and cost-effective non-invasive alternative for CAV surveillance post-HT, outperforming ICA in terms of safety, logistical aspects, and economic burden.

17 April 2025 in Medicina
Verified
Journal Article
Open access
PDF file
GCGiorgia Cibin
Giorgia Cibin
Augusto D’OnofrioAugusto D’Onofrio
Augusto D’Onofrio
Giulia LorenzoniGiulia Lorenzoni
Giulia Lorenzoni
VLValentina Lombardi
Valentina Lombardi
EBEmma Bergonzoni
Emma Bergonzoni
Giacomo GerosaGiacomo Gerosa
Giacomo Gerosa
Background and Objectives: Prosthesis–patient mismatch (PPM) after surgical aortic valve replacement (SAVR) is associated with worse clinical outcomes and worse valve durability. The aim of this retrospective single-center study was to evaluate the consistency between predicted PPM (PPMp) and measured PPM (PPMm) after SAVR with three different bioprostheses. Materials and Methods: We analyzed data of all consecutive patients who underwent surgical aortic valve replacement with Magna Ease, Intuity, and Inspiris Resilia bioprostheses (Edwards Lifesciences, Irvine, CA, USA) at our institution. PPM was defined if EOAi ≤ 0.85 cm2/m2. PPMm was determined by institutional echo lab-measured EOAi on discharge-day echocardiogram. PPMp was assessed using reference values for each valve model and size indexed to BSA based on height, weight, prosthesis type, and size. For the overall population and for the three valve types we evaluated the sensitivity, specificity, positive predicted value, negative predicted value, and accuracy of PPMp. Furthermore, the consistency between PPMm and PPMp were evaluated according to prosthesis type, size, stent internal diameter (ID), and true ID. Results: A total of 1323 patients underwent SAVR; complete hemodynamic data were available for 872 patients, who represent the population of our study. Magna Ease, Intuity, and Inspiris Resilia were implanted in 446 (51.1%), 341 (39.1%), and 85 (9.7%) patients, respectively. In 635 out of 872 cases (72.8%), PPMp was consistent with PPMm (Magna Ease: 321/446, 72%; Inspiris Resilia: 58/85, 68.2%; Intuity: 256/341, 75%). Overall, the sensitivity, specificity, positive predicted value, negative predicted value, and accuracy of PPMp were 0.26, 0.83, 0.24, 0.84, and 0.73, respectively (Magna Ease: 0.21, 0.82, 0.3, 0.8, and 0.72; Inspiris Resilia: 0.11, 0.82, 0.14, 0.79, and 0.68; Intuity: 0.45, 0.78, 0.19, 0.93, and 0.75). Conclusions: The consistency between PPMp and PPMm was suboptimal. We did not observe differences between PPMp and PPMm among different valve types. Discordance between PPMp and PPMm was more evident in smaller valve sizes. When implanting small valves, the evaluation of PPMp should be used with caution to avoid unexpected PPMm.

19 October 2023 in ASAIO Journal
Verified
Journal Article
Open access
EIEnrico G. Italiano
Enrico G. Italiano
FBFrancesco Bertelli
Francesco Bertelli
ICIrene Cao
Irene Cao
RMRaffaella Motta
Raffaella Motta
Giovanni Di SalvoGiovanni Di Salvo
Giovanni Di Salvo
MPMassimo A. Padalino
Massimo A. Padalino
The current use of intracorporeal left ventricular assist devices in children is still limited by small body dimensions. Many children weighing of less than 30 kg requiring durable mechanical circulatory support are implanted with the Berlin Heart EXCOR, a paracorporeal device. We present the case of a girl aged 10 years with a body surface area of 1.01 m2 undergoing a safe and effective HeartMate3 implantation despite extremely small thoracic dimensions. Using computed tomography-derived three-dimensional (3D) reconstruction, it was possible to simulate several device positions finding the best HeartMate3 lodging. Simulation-guided pump placement was then obtained in the operating room. Normal HeartMate3 functioning was registered until heart transplant. Our experience shows that preoperative planning and virtual fitting simulation can be effective to assess safety of HeartMate3 implantation even in small children. The 3D reconstruction and simulation may help to increase the pool of children candidates for this device, even though a larger experience is needed to assess the risk profile of the HeartMate3 in such small patients.

21 February 2024 in Artificial Organs
Verified
Journal Article
Open access
ICIrene Cao
Irene Cao
EIEnrico Giuseppe Italiano
Enrico Giuseppe Italiano
FBFrancesco Bertelli
Francesco Bertelli
RMRaffaella Motta
Raffaella Motta
BCBiagio Castaldi
Biagio Castaldi
MPMassimo A. Padalino
Massimo A. Padalino
Background: Mechanical cardiac support is currently an effective strategy to reduce morbidity and mortality in pediatric patients. However, solid evidence regarding the feasibility of intracorporeal devices in children still needs to be provided. We report our 10‐year experience with intracorporeal left ventricular assist devices (LVAD) in children.Materials and Methods: We included all patients undergoing intracorporeal, continuous‐flow LVAD implantation between 2012 and 2022. Baseline and postoperative data were collected from the institutional database.Results: Seven HeartWare and 4 HeartMate3 were implanted in 11 patients (median age 13.9 years, median body surface area – BSA – 1.42 m2, IQR 1.06–1.68). The most frequent indication to LVAD implant was dilated cardiomyopathy (72.7%). All candidates underwent a thorough preoperative advanced imaging. Three‐dimensional reconstructions and implant fit simulation were performed when BSA was <1.2 m2, weight <30 kg, or internal transverse thoracic diameter 1.0 m2. In borderline cases, the 3D reconstruction with implant fit simulation can effectively help to identify those patients who can safely undergo intrathoracic LVAD implantation.

24 July 2026 in JTCVS Open
Verified
Journal Article
Open access
EBEmma Bergonzoni
Emma Bergonzoni
ICIrene Cao
Irene Cao
LVLuca Vedovelli
Luca Vedovelli
MHMark Hazekamp
Mark Hazekamp
JHJürgen Hörer
Jürgen Hörer
MPMassimo A. Padalino
Massimo A. Padalino